<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Uridine triacetate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Uridine triacetate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Uridine triacetate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9537" href="/d/html/9537.html" rel="external">see "Uridine triacetate: Drug information"</a> and <a class="drug drug_patient" data-topicid="104066" href="/d/html/104066.html" rel="external">see "Uridine triacetate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F46170543"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vistogard;</li>
<li>Xuriden</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F46149883"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote</span>;</li>
<li>
<span class="list-set-name">Endocrine and Metabolic Agent, Miscellaneous</span></li></ul></div>
<div class="block dop drugH1Div" id="F45069133"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Package (packet) size of products is different (Vistogard: 10 g/packet, Xuridine: 2 g/packet of uridine triacetate); use caution with product selection and calculations.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="82492f13-4d85-4def-80e8-9a3cccf65918">Fluoropyrimidine overdose/overexposure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fluoropyrimidine (fluorouracil/</b>
<b>capecitabine</b>
<b>) overdose/overexposure:</b> Children and Adolescents: Vistogard<b>:</b> Oral: 6.2 g/m<sup>2</sup> (maximum dose: 10 g/dose [1 packet]) every 6 hours for 20 doses beginning as soon as possible after overdose or early-onset toxicity within 96 hours after the end of fluorouracil or capecitabine administration. May be dosed as g or teaspoon; measure dose using either a scale (accurate to at least 0.1 g) or a graduated teaspoon (accurate to <sup>1</sup>/<sub>4</sub> teaspoon). See table for BSA range dose recommendations (including rounding) for g and teaspoon doses. <b>Note:</b> Administer the full course of 20 doses, even if the patient appears or feels well.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:center;">
<b>Uridine Triacetate Dose (g or teaspoons) Based on Body Surface Area (BSA; m<sup>2</sup>)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Patient BSA</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Dose of Uridine Triacetate (Vistogard) 6.2 g/m<sup>2</sup>/dose<sup>a</sup></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Dose in grams</p></th>
<th align="center">
<p style="text-indent:0em;">Dose in graduated teaspoons</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<b>Note:</b> One Vistogard packet contains uridine triacetate 10 g.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Doses rounded by BSA to achieve approximate dose; administer each dose every 6 hours for 20 doses.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b</sup>May use 1 entire 10 g packet without weighing or measuring. Do not exceed 10 g/dose</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">0.34 to 0.44 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">2.1 to 2.7 g</p></td>
<td align="center">
<p style="text-indent:0em;">1 tsp</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">0.45 to 0.55 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">2.8 to 3.4 g</p></td>
<td align="center">
<p style="text-indent:0em;">1 <sup>1</sup>/<sub>4</sub> tsp</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">0.56 to 0.66 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">3.5 to 4.1 g</p></td>
<td align="center">
<p style="text-indent:0em;">1 <sup>1</sup>/<sub>2</sub> tsp</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">0.67 to 0.77 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">4.2 to 4.8 g</p></td>
<td align="center">
<p style="text-indent:0em;">1 <sup>3</sup>/<sub>4</sub> tsp</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">0.78 to 0.88 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">4.9 to 5.4 g</p></td>
<td align="center">
<p style="text-indent:0em;">2 tsp</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">0.89 to 0.99 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">5.5 to 6.1 g</p></td>
<td align="center">
<p style="text-indent:0em;">2 <sup>1</sup>/<sub>4</sub> tsp</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1 to 1.1 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">6.2 to 6.8 g</p></td>
<td align="center">
<p style="text-indent:0em;">2 <sup>1</sup>/<sub>2</sub> tsp</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1.11 to 1.21 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">6.9 to 7.5 g</p></td>
<td align="center">
<p style="text-indent:0em;">2 <sup>3</sup>/<sub>4</sub> tsp</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1.22 to 1.32 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">7.6 to 8.1 g</p></td>
<td align="center">
<p style="text-indent:0em;">3 tsp</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1.33 to 1.43 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">8.2 to 8.8 g</p></td>
<td align="center">
<p style="text-indent:0em;">3 <sup>1</sup>/<sub>4</sub> tsp</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥1.44 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">10 g<sup> b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">1 full packet<sup>b </sup></p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ca234f98-99dc-47af-a672-a076e9769a23">Hereditary orotic aciduria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary orotic aciduria</b>: Infants, Children, and Adolescents: Oral: Xuridine: Initial: 60 mg/kg once daily; may increase to 120 mg/kg (maximum daily dose: 8 g/<b>day</b> ) for insufficient efficacy (eg, urine orotic acid levels remaining above normal or increasing above the usual/expected range for the patient; lab values affected by orotic aciduria [red or white blood cell indices] worsening; worsening disease signs/symptoms). May be dosed as g or teaspoon; measure dose using either a scale (accurate to at least 0.1 g) or a graduated teaspoon (accurate to the fraction being measured). See table for weight-band dosing (including dose rounding).</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:center;">
<b>Uridine Triacetate (Xuridine) Dose (g or teaspoons) Based on Body Weight (kg)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Patient weight</p></th>
<th align="center">
<p style="text-indent:0em;">
<b>60 mg/kg<sup>a</sup> dose</b></p>
<p style="text-indent:0em;">Dose in grams</p>
<p style="text-indent:0em;">(dose in teaspoons<sup>b</sup>)</p></th>
<th align="center">
<p style="text-indent:0em;">120 mg/kg<sup>a</sup> dose</p>
<p style="text-indent:0em;">Dose in grams</p>
<p style="text-indent:0em;">(dose in teaspoons<sup>b</sup>)</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Doses rounded (by the manufacturer) by weight category to achieve approximate dose level</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup>A 2 gram uridine triacetate (Xuriden) packet contains approximately <sup>3</sup>/<sub>4</sub> tsp</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">≤5 kg</p></td>
<td align="center">
<p style="text-indent:0em;">0.4 g</p>
<p style="text-indent:0em;">(<sup>1</sup>/<sub>8</sub> tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">0.8 g</p>
<p style="text-indent:0em;">(<sup>1</sup>/<sub>4</sub> tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">6 to 10 kg</p></td>
<td align="center">
<p style="text-indent:0em;">0.4 to 0.6 g</p>
<p style="text-indent:0em;">(<sup>1</sup>/<sub>4</sub> tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">0.8 to 1.2 g</p>
<p style="text-indent:0em;">(<sup>1</sup>/<sub>2</sub> tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">11 to 15 kg</p></td>
<td align="center">
<p style="text-indent:0em;">0.7 to 0.9 g</p>
<p style="text-indent:0em;">(<sup>1</sup>/<sub>2</sub> tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">1.4 to 1.8 g</p>
<p style="text-indent:0em;">(<sup>3</sup>/<sub>4</sub> tsp<sup></sup> or 1 entire packet)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">16 to 20 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 1.2 g</p>
<p style="text-indent:0em;">(<sup>1</sup>/<sub>2</sub> tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 2.4 g</p>
<p style="text-indent:0em;">(1 tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">21 to 25 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1.3 to 1.5 g</p>
<p style="text-indent:0em;">(<sup>1</sup>/<sub>2</sub> tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">2.6 to 3 g</p>
<p style="text-indent:0em;">(1 tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">26 to 30 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1.6 to 1.8 g</p>
<p style="text-indent:0em;">(<sup>3</sup>/<sub>4</sub> tsp or 1 entire packet)</p></td>
<td align="center">
<p style="text-indent:0em;">3.2 to 3.6 g</p>
<p style="text-indent:0em;">(1<sup>1</sup>/<sub>4</sub> tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">31 to 35 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1.9 to 2.1 g</p>
<p style="text-indent:0em;">(<sup>3</sup>/<sub>4</sub> tsp or 1 entire packet)</p></td>
<td align="center">
<p style="text-indent:0em;">3.8 to 4.2 g</p>
<p style="text-indent:0em;">(1<sup>1</sup>/<sub>2</sub> tsp or 2 entire packets)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">36 to 40 kg</p></td>
<td align="center">
<p style="text-indent:0em;">2.2 to 2.4 g</p>
<p style="text-indent:0em;">(1 tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">4.4 to 4.8 g</p>
<p style="text-indent:0em;">(1<sup>3</sup>/<sub>4</sub> tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">41 to 45 kg</p></td>
<td align="center">
<p style="text-indent:0em;">2.5 to 2.7 g</p>
<p style="text-indent:0em;">(1 tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">5 to 5.4 g</p>
<p style="text-indent:0em;">(2 tsp or 3 entire packets)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">46 to 50 kg</p></td>
<td align="center">
<p style="text-indent:0em;">2.8 to 3 g</p>
<p style="text-indent:0em;">(1 tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">5.6 to 6 g</p>
<p style="text-indent:0em;">(2 tsp or 3 entire packets)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">51 to 55 kg</p></td>
<td align="center">
<p style="text-indent:0em;">3.1 to 3.3 g</p>
<p style="text-indent:0em;">(1<sup>1</sup>/<sub>4</sub> tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">6.2 to 6.6 g</p>
<p style="text-indent:0em;">(2<sup>1</sup>/<sub>4</sub> tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">56 to 60 kg</p></td>
<td align="center">
<p style="text-indent:0em;">3.4 to 3.6 g</p>
<p style="text-indent:0em;">(1<sup>1</sup>/<sub>4</sub> tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">6.8 to 7.2 g</p>
<p style="text-indent:0em;">(2<sup>1</sup>/<sub>2</sub> tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">61 to 65 kg</p></td>
<td align="center">
<p style="text-indent:0em;">3.7 to 3.9 g</p>
<p style="text-indent:0em;">(1<sup>1</sup>/<sub>2</sub> tsp or 2 entire packets)</p></td>
<td align="center">
<p style="text-indent:0em;">7.4 to 7.8 g</p>
<p style="text-indent:0em;">(2<sup>1</sup>/<sub>2</sub> tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">66 to 70 kg</p></td>
<td align="center">
<p style="text-indent:0em;">4 to 4.2 g</p>
<p style="text-indent:0em;">(1<sup>1</sup>/<sub>2</sub> tsp or 2 entire packets)</p></td>
<td align="center">
<p style="text-indent:0em;">8 g</p>
<p style="text-indent:0em;">(2<sup>3</sup>/<sub>4</sub> tsp or 4 entire packets)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">71 to 75 kg</p></td>
<td align="center">
<p style="text-indent:0em;">4.3 to 4.5 g</p>
<p style="text-indent:0em;">(1<sup>1</sup>/<sub>2</sub> tsp or 2 entire packets)</p></td>
<td align="center">
<p style="text-indent:0em;">8 g</p>
<p style="text-indent:0em;">(2<sup>3</sup>/<sub>4</sub> tsp or 4 entire packets)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;75 kg</p></td>
<td align="center">
<p style="text-indent:0em;">6 g</p>
<p style="text-indent:0em;">(2 tsp or 3 entire packets)</p></td>
<td align="center">
<p style="text-indent:0em;">8 g</p>
<p style="text-indent:0em;">(2<sup>3</sup>/<sub>4</sub> tsp or 4 entire packets)</p></td></tr></tbody></table></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51193130"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51193131"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doa drugH1Div" id="F7976696"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9537" href="/d/html/9537.html" rel="external">see "Uridine triacetate: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="82492f13-4d85-4def-80e8-9a3cccf65918">Fluoropyrimidine overdose/overexposure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fluoropyrimidine overdose/overexposure:</b> Initiate within 96 hours after the end of fluorouracil or capecitabine administration: <b>Oral:</b> 10 g every 6 hours for 20 doses beginning as soon as possible after overdose or early-onset toxicity (Ma 2017). Administer the full course of 20 doses, even if the patient appears or feels well.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off label:</i> &gt;96 hours after the end of fluorouracil or capecitabine administration (based on limited data): Uridine triacetate may be effective in managing severe GI, hematologic, cardiac, and neurologic toxicities when initiated beyond 96 hours following the end of fluorouracil/capecitabine administration. Case reports of use &gt;96 hours post fluorouracil/capecitabine administration described improvement in severe toxicity associated with these agents; reports included a patient later determined to be homozygous for dihydropyrimidine dehydrogenase gene mutation, a heterozygous carrier, and another later found to have a thymidylate synthase gene variation (Baldeo 2018; Jacob 2022; Zurayk 2019).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ca234f98-99dc-47af-a672-a076e9769a23">Hereditary orotic aciduria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary orotic aciduria:</b>
<b>Oral:</b> Initial: 60 mg/kg once daily; increase to 120 mg/kg (maximum: 8 g) for insufficient efficacy (eg, urine orotic acid levels remaining above normal or increasing above the usual/expected range for the patient; lab values affected by orotic acid [red or white blood cell indices] worsening; worsening disease signs/symptoms).</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:center;">
<b>Uridine Triacetate Daily Dose for Hereditary Orotic Aciduria Based on Weight (kg)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Patient weight</p></th>
<th align="center">
<p style="text-indent:0em;">60 mg/kg<sup>a</sup> dose</p>
<p style="text-indent:0em;">Dose in grams</p>
<p style="text-indent:0em;">(dose in teaspoons<sup>b</sup>)</p></th>
<th align="center">
<p style="text-indent:0em;">120 mg/kg<sup>a</sup> dose</p>
<p style="text-indent:0em;">Dose in grams</p>
<p style="text-indent:0em;">(dose in teaspoons<sup>b</sup>)</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<b>Note:</b> One Xuriden packet contains uridine triacetate 2 g.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Doses rounded (by the manufacturer) by weight category to achieve approximate dose level.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup>A 2 gram uridine triacetate (Xuriden) packet contains approximately <sup>3</sup>/<sub>4</sub> tsp.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="center">
<p style="text-indent:0em;">≤5 kg</p></td>
<td align="center">
<p style="text-indent:0em;">0.4 g</p>
<p style="text-indent:0em;">(<sup>1</sup>/<sub>8</sub> tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">0.8 g</p>
<p style="text-indent:0em;">(<sup>1</sup>/<sub>4</sub> tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">6 to 10 kg</p></td>
<td align="center">
<p style="text-indent:0em;">0.4 to 0.6 g</p>
<p style="text-indent:0em;">(<sup>1</sup>/<sub>4</sub> tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">0.8 to 1.2 g</p>
<p style="text-indent:0em;">(<sup>1</sup>/<sub>2</sub> tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">11 to 15 kg</p></td>
<td align="center">
<p style="text-indent:0em;">0.7 to 0.9 g</p>
<p style="text-indent:0em;">(<sup>1</sup>/<sub>2</sub> tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">1.4 to 1.8 g</p>
<p style="text-indent:0em;">(<sup>3</sup>/<sub>4</sub> tsp or 1 entire packet)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">16 to 20 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 1.2 g</p>
<p style="text-indent:0em;">(<sup>1</sup>/<sub>2</sub> tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 2.4 g</p>
<p style="text-indent:0em;">(1 tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">21 to 25 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1.3 to 1.5 g</p>
<p style="text-indent:0em;">(<sup>1</sup>/<sub>2</sub> tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">2.6 to 3 g</p>
<p style="text-indent:0em;">(1 tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">26 to 30 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1.6 to 1.8 g</p>
<p style="text-indent:0em;">(<sup>3</sup>/<sub>4</sub> tsp or 1 entire packet)</p></td>
<td align="center">
<p style="text-indent:0em;">3.2 to 3.6 g</p>
<p style="text-indent:0em;">(1<sup>1</sup>/<sub>4</sub> tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">31 to 35 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1.9 to 2.1 g</p>
<p style="text-indent:0em;">(<sup>3</sup>/<sub>4</sub> tsp or 1 entire packet)</p></td>
<td align="center">
<p style="text-indent:0em;">3.8 to 4.2 g</p>
<p style="text-indent:0em;">(1<sup>1</sup>/<sub>2</sub> tsp or 2 entire packets)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">36 to 40 kg</p></td>
<td align="center">
<p style="text-indent:0em;">2.2 to 2.4 g</p>
<p style="text-indent:0em;">(1 tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">4.4 to 4.8 g</p>
<p style="text-indent:0em;">(1<sup>3</sup>/<sub>4</sub> tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">41 to 45 kg</p></td>
<td align="center">
<p style="text-indent:0em;">2.5 to 2.7 g</p>
<p style="text-indent:0em;">(1 tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">5 to 5.4 g</p>
<p style="text-indent:0em;">(2 tsp or 3 entire packets)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">46 to 50 kg</p></td>
<td align="center">
<p style="text-indent:0em;">2.8 to 3 g</p>
<p style="text-indent:0em;">(1 tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">5.6 to 6 g</p>
<p style="text-indent:0em;">(2 tsp or 3 entire packets)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">51 to 55 kg</p></td>
<td align="center">
<p style="text-indent:0em;">3.1 to 3.3 g</p>
<p style="text-indent:0em;">(1<sup>1</sup>/<sub>4</sub> tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">6.2 to 6.6 g</p>
<p style="text-indent:0em;">(2<sup>1</sup>/<sub>4</sub> tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">56 to 60 kg</p></td>
<td align="center">
<p style="text-indent:0em;">3.4 to 3.6 g</p>
<p style="text-indent:0em;">(1<sup>1</sup>/<sub>4</sub> tsp)</p></td>
<td align="center">
<p style="text-indent:0em;">6.8 to 7.2 g</p>
<p style="text-indent:0em;">(2<sup>1</sup>/<sub>2</sub> tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">61 to 65 kg</p></td>
<td align="center">
<p style="text-indent:0em;">3.7 to 3.9 g</p>
<p style="text-indent:0em;">(1<sup>1</sup>/<sub>2</sub> tsp or 2 entire packets)</p></td>
<td align="center">
<p style="text-indent:0em;">7.4 to 7.8 g</p>
<p style="text-indent:0em;">(2<sup>1</sup>/<sub>2</sub> tsp)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">66 to 70 kg</p></td>
<td align="center">
<p style="text-indent:0em;">4 to 4.2 g</p>
<p style="text-indent:0em;">(1<sup>1</sup>/<sub>2</sub> tsp or 2 entire packets)</p></td>
<td align="center">
<p style="text-indent:0em;">8 g</p>
<p style="text-indent:0em;">(2<sup>3</sup>/<sub>4</sub> tsp or 4 entire packets)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">71 to 75 kg</p></td>
<td align="center">
<p style="text-indent:0em;">4.3 to 4.5 g</p>
<p style="text-indent:0em;">(1<sup>1</sup>/<sub>2</sub> tsp or 2 entire packets)</p></td>
<td align="center">
<p style="text-indent:0em;">8 g</p>
<p style="text-indent:0em;">(2<sup>3</sup>/<sub>4</sub> tsp or 4 entire packets)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;75 kg</p></td>
<td align="center">
<p style="text-indent:0em;">6 g</p>
<p style="text-indent:0em;">(2 tsp or 3 entire packets)</p></td>
<td align="center">
<p style="text-indent:0em;">8 g</p>
<p style="text-indent:0em;">(2<sup>3</sup>/<sub>4</sub> tsp or 4 entire packets)</p></td></tr></tbody></table></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992033"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989326"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F44661391"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Gastrointestinal: Vomiting (10%), nausea (5%), diarrhea (3%)</p></div>
<div class="block coi drugH1Div" id="F45069168"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F45069169"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:0em;display:inline">There are no warnings listed in the manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F46170544"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vistogard: 10 g (4 ea, 20 ea) [orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xuriden: 2 g (1 ea, 30 ea) [orange flavor]</p></div>
<div class="block geq drugH1Div" id="F46170542"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F46251911"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Vistogard Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g (per each): $5,056.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Xuriden Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $945.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F11234389"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Fluorouracil accidental overdose/overexposure: Uridine triacetate (formerly called vistonuridine) is available through select specialty pharmacies. Procurement information is available from Wellstat Therapeutics at 1-800-914-0071 or https://www.vistogard.com/Professional/How-to-Order.</p></div>
<div class="block admp drugH1Div" id="F52614424"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Granules: Measure the prescribed dose using either a scale accurate to at least 0.1 gram, or a graduated teaspoon, accurate to the fraction of the dose to be administered. Discard the unused portion of granules after measuring out the dose. Do not chew granules. May be administered without regard to meals (food does not have an effect on uridine exposure).</p>
<p style="text-indent:-2em;margin-left:4em;">Fluoropyrimidine overdose/overexposure: Vistogard: Administer orally; begin as soon as possible after overdose or early-onset toxicity within 96 hours following the end of fluorouracil or capecitabine overdose/overexposure (Ma 2017). Administer the full treatment course (all 20 doses), even if patient appears or feels well.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Oral:</i> Mix each dose with 3 to 4 ounces of soft food (applesauce, pudding, or yogurt). Administer within 30 minutes of preparation (in soft food such as applesauce, pudding, or yogurt); do not chew granules. Following administration, drink at least 4 ounces (120 mL) of water. If patient vomits within 2 hours of taking dose, administer another complete dose as soon as possible after vomiting episode and then administer the next dose at the regularly scheduled time. If a dose is missed, administer the missed dose as soon as possible and then administer the next dose at the regularly scheduled time.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Nasogastric (NG) or gastrostomy tube administration:</i> If necessary to administer through a nasogastric or gastrostomy tube (due to stomatitis or mucositis), mix with thickening agent (see Preparation for Administration); following administration, flush tube with water.</p>
<p style="text-indent:-2em;margin-left:4em;">Hereditary orotic aciduria: Xuriden:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral administration with food:</i> Mix each dose with 3 to 4 ounces of applesauce, pudding, or yogurt in a small clean container and administer immediately; do not chew the granules. Do not save applesauce, pudding, or yogurt mixture for later use. Following administration drink at least 4 ounces (120 mL) of water.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral administration in milk or infant formula:</i> May be mixed with milk or infant formula for patients receiving a dose of up to 2 grams (<sup>3</sup>/<sub>4</sub> teaspoon). See Preparation for Administration for oral syringe preparation instructions. Place the tip of the oral syringe in the patient’s mouth between the cheek and gum at the back of the mouth. Gently push the plunger all the way down. Refill the syringe with another 5 mL of milk/infant formula. Gently swirl the syringe to rinse remaining uridine triacetate granules from the syringe barrel. Place the tip of the syringe in the patient’s mouth between the cheek and gum at the back of the mouth. Gently push the plunger all the way down. May follow with a bottle of milk or infant formula.</p></div>
<div class="block adm drugH1Div" id="F7976698"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Granules: Measure the prescribed dose using either a scale accurate to at least 0.1 gram, or a graduated teaspoon, accurate to the fraction of the dose to be administered (accurate to <sup>1</sup>/<sub>4</sub> teaspoonful). Discard the unused portion of granule packet after measuring out the dose. Do not chew granules. May be administered without regard to meals (food does not have an effect on uridine exposure).</p>
<p style="text-indent:-2em;margin-left:4em;">Fluoropyrimidine overdose/overexposure: Administer orally; begin as soon as possible after overdose or early-onset toxicity within 96 hours following the end of fluorouracil or capecitabine overdose/overexposure (Ma 2017). Based on limited data, uridine triacetate may be effective in managing severe toxicities when initiated beyond 96 hours (off-label) after fluorouracil or capecitabine administration (Baldeo 2018; Jacob 2022; Zurayk 2019). Administer within 30 minutes of preparation (in soft food such as applesauce, pudding, or yogurt), followed by at least 120 mL water. If patient vomits within 2 hours of taking dose, administer another complete dose as soon as possible after vomiting episode. If a dose is missed, administer the missed dose as soon as possible and then administer the next dose at the regularly scheduled time. If necessary to administer through a nasogastric or gastrostomy tube (due to stomatitis or mucositis), mix with thickening agent (see Preparation for Administration); following administration, flush tube with water. Administer the full treatment course (all 20 doses), even if the patient appears or feels well.</p>
<p style="text-indent:-2em;margin-left:4em;">Hereditary orotic aciduria: May be mixed in food (ie, 3 to 4 ounces of applesauce, pudding, or yogurt) and administered immediately, followed by drinking at least 120 mL water. Do not chew the granules. Do not save for later use.</p></div>
<div class="block sts drugH1Div" id="F45069191"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Fluoropyrimidine overdose/overexposure: Use within 30 minutes of preparation in soft food. </p>
<p style="text-indent:-2em;margin-left:2em;">Hereditary orotic aciduria:  If administering in food (applesauce, pudding, or yogurt), use immediately after preparation.</p></div>
<div class="block usep drugH1Div" id="F53570788"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Xuriden: Treatment of hereditary orotic aciduria (FDA approved in pediatric patients [age not specified] and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Vistogard: Emergency treatment of fluorouracil or capecitabine overdose (regardless of the presence of symptoms) or early-onset, severe or life-threatening cardiac or CNS toxicity and/or early-onset, unusually severe adverse reactions (eg, GI toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (FDA approved in pediatric patients [age not specified] and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Uridine triacetate is not recommended for nonemergent treatment of adverse reactions associated with fluorouracil or capecitabine (because it may diminish efficacy of these medications). Safety and efficacy of uridine triacetate initiated more than 96 hours following the end of fluorouracil or capecitabine administration have not been established.</p></div>
<div class="block cyt drugH1Div" id="F13300196"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F8018477"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F45069166"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies. Information related to the use of uridine triacetate for the treatment of hereditary orotic aciduria and fluoropyrimidine overdose/severe (life-threatening) toxicity during pregnancy is limited; monitor closely, dose adjustments may be required (Bensen 1991). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant patients if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>
<div class="block mopp drugH1Div" id="F53570789"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Fluoropyrimidine overdose/overexposure: CBC with differential; gastrointestinal toxicity (Hidalgo 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Hereditary orotic aciduria: Urine orotic acid level, red or white blood cell indices</p></div>
<div class="block pha drugH1Div" id="F7976691"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Uridine triacetate is an acetylated form of uridine which is deacetylated following administration to provide circulating uridine in patients with hereditary orotic aciduria. In patients with fluorouracil overdose or overexposure, uridine competes with fluorouridine triphosphate, a fluorouracil metabolite for incorporation into RNA of hematopoietic progenitor cells and gastrointestinal mucosal cells to reduce fluorouracil toxicity in normal tissues (Hidalgo 2000; Ma 2017).</p></div>
<div class="block phk drugH1Div" id="F7976693"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Hereditary orotic aciduria: Oral exogenous uridine improves hematologic abnormalities within 2 to 3 weeks; urinary orotic acid reduced within 1 to 2 weeks of initiating therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: Hereditary orotic aciduria: Hematologic abnormalities and orotic aciduria return within days up to 2 to 3 weeks after discontinuation or dose reduction.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Distributes into cells; crosses the blood brain barrier</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Deacetylated (by nonspecific esterases) to uridine and free acetate (Hidalgo 2000)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 2 to 2.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine; also catabolic metabolism in tissues.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/uridine-triacetate-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30013790">
<a name="30013790"></a>Baldeo C, Vishnu P, Mody K, Kasi PM. Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications [published online July 4, 2018]. <i>SAGE Open Med Case Rep</i>. doi: 10.1177/2050313X18786405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/uridine-triacetate-pediatric-drug-information/abstract-text/30013790/pubmed" id="30013790" target="_blank">30013790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1776631">
<a name="1776631"></a>Bensen JT, Nelson LH, Pettenati MJ, et al. First report of management and outcome of pregnancies associated with hereditary orotic aciduria. <i>Am J Med Genet</i>. 1991;41(4):426-431.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/uridine-triacetate-pediatric-drug-information/abstract-text/1776631/pubmed" id="1776631" target="_blank">1776631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10623707">
<a name="10623707"></a>Hidalgo M, Villalona-Calero MA, Eckhardt SG, et al, “Phase I and Pharmacologic Study of PN401 and Fluorouracil in Patients With Advanced Solid Malignancies,” <i>J Clin Oncol</i>, 2000, 18(1):167-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/uridine-triacetate-pediatric-drug-information/abstract-text/10623707/pubmed" id="10623707" target="_blank">10623707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36160401">
<a name="36160401"></a>Jacob A, Sekkath Veedu J, Selene I, et al. Case report: uridine triacetate in the management of delayed onset 5-fluorouracil toxicity: a case report and review of literature. <i>Front Pharmacol</i>. 2022;13:977734. doi:10.3389/fphar.2022.977734<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/uridine-triacetate-pediatric-drug-information/abstract-text/36160401/pubmed" id="36160401" target="_blank">36160401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27622829">
<a name="27622829"></a>Ma WW, Saif MW, El-Rayes BF, et al. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. <i>Cancer</i>. 2017;123(2):345-356. doi:10.1002/cncr.30321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/uridine-triacetate-pediatric-drug-information/abstract-text/27622829/pubmed" id="27622829" target="_blank">27622829</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Vistogard (uridine triacetate) [prescribing information]. Rockville, MD: Wellstat Therapeutics Corporation; February 2017.</div>
</li>
<li>
<div class="reference">
                  Xuriden (uridine triacetate) [prescribing information]. Rockville, MD; Wellstat Therapeutics Corporation; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28950804">
<a name="28950804"></a>Zurayk M, Keung YK, Yu D, Hu EH. Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature. <i>J Oncol Pharm Pract</i>. 2019;25(1):234-238. doi: 10.1177/1078155217732141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/uridine-triacetate-pediatric-drug-information/abstract-text/28950804/pubmed" id="28950804" target="_blank">28950804</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 109475 Version 45.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
